Technology Transfer of Pentavalent Meningitis Conjugate Vaccine

Biovac aims to establish secure, affordable manufacturing of NmCV-5 to eliminate meningococcal disease in Sub-Saharan Africa. Through technology transfer from EuBiologics, Biovac will obtain WHO PQ for a fully liquid NmCV-5, including serogroup X, ensuring sustainable supply for routine immunization and reactive vaccination campaigns. By becoming a priority supplier, Biovac will improve vaccine accessibility at competitive pricing, aligning with the Defeating Meningitis by 2030 Global Road Map. While MenAfriVac eliminated serogroup A, outbreaks due to serogroups C, W, and X persist, requiring a broader solution. Though SIIPL’s NmCV-5 is prequalified, additional low-cost, multivalent vaccines are essential for supply stability. With a target price of ≤ $3 per dose, Biovac’s NmCV-5 will enhance public health impact by expanding meningitis prevention across Africa.